Tango Therapeutics (TNGX) Change in Receivables (2023)

Tango Therapeutics (TNGX) posted quarterly Change in Receivables of -$2.0 million for Q1 2023.

Tango Therapeutics (TNGX) Change in Receivables (2023) Analysis & Trends

Tango Therapeutics' Change in Receivables history runs 1 years deep, the most recent figure standing at -$2.0 million for Q1 2023.

In Q1 2023, Change in Receivables changed N/A year-over-year to -$2.0 million; the TTM figure through Dec 2023 stood at -$2.0 million (changed N/A YoY), while the FY2023 annual figure was -$2.0 million, changed N/A from the prior year.
Change in Receivables for Q1 2023 stood at -$2.0 million.
The five-year high for Change in Receivables was -$2.0 million in Q1 2023, with the low at -$2.0 million in Q1 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Receivables (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	140.20 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	838.50 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	117.58 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-483,662.49
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	31.60 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	37.16 Mn
10	Tango Therapeutics	4.32 Bn	3.30 Bn	-	-

Historic Data

Download Data

Date	Value
Mar 31, 2023	-2.00 Mn
Mar 31, 2023	-2.00 Mn